Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study

Abstract Background Vonoprazan‐amoxicillin (VA) dual therapy has been shown to achieve acceptable cure rates for treatment of Helicobacter pylori ( H. pylori ) in Japan. Its effectiveness in other regions is unknown. We aimed to explore the efficacy of VA dual therapy as first‐line treatment for H. pylori infection in China. Methods This was a single center, prospective, randomized clinical pilot study conducted in China. Treatment naive H. pylori infected patients were randomized to receive either low‐ or high‐dose amoxicillin‐vonoprazan consisting of amoxicillin 1 g either b.i.d. or t.i.d plus VPZ 20 mg b.i.d for 7 or 10 days. 13 C‐urea breath tests were used to access the cure rate at least 4 weeks after treatment. Results Three hundred and twenty‐three patients were assessed, and 119 subjects were randomized. The eradication rates of b.i.d. amoxicillin for 7 and 10 days, t.i.d. amoxicillin for 7 and 10 days were 66.7% (16/24), 89.2% (33/37), 81.0% (17/21), and 81.1% (30/37) ( p = .191) by intention‐to‐treat analysis, respectively, and 72.7% (16/22), 89.2% (33/37), 81.0% (17/21), and 81.1% (30/37) ( p = .454) by per‐protocol analysis, respectively. Conclusion Neither 7‐ or 10‐day VA dual therapy with b.i.d. or t.i.d. amoxicillin provides satisfied efficacy as the first‐line treatment for H. pylori infection in China. Further optimization is needed.